Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

This study has been terminated.
Sponsor:
Information provided by:
Enzon Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00023166
First received: August 24, 2001
Last updated: June 23, 2005
Last verified: March 2004
  Purpose

Studies of PEG-paclitaxel have been terminated


Condition Intervention Phase
Neoplasm
Lymphomas
Neoplasm Metastasis
Drug: PEG-paclitaxel
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas

Resource links provided by NLM:


Further study details as provided by Enzon Pharmaceuticals, Inc.:

Study Start Date: May 2001
Estimated Study Completion Date: May 2002
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

None - Study has been terminated.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00023166     History of Changes
Other Study ID Numbers: PTX-5001
Study First Received: August 24, 2001
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Enzon Pharmaceuticals, Inc.:
Phase I
Open label
Safety/efficacy
Lymphomas
Advanced primary and/or metastatic solid tumors
Neoplasms
Neoplasm metastasis

Additional relevant MeSH terms:
Lymphoma
Neoplasm Metastasis
Neoplasms
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplastic Processes
Pathologic Processes
Paclitaxel
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 25, 2014